MétaCan
Menu
← Back to cohort
Record W4408857150 · doi:10.2215/cjn.0000000693

Efficacy and Safety of Sodium-Glucose Cotransporter-2 Inhibitors in Patients with and without Advanced CKD

2025· review· en· W4408857150 on OpenAlexafffund
Elenjickal Elias John, Christoforos K Travlos, Judy Luu, Serge Lemay, Rita S. Suri, Thomas A. Mavrakanas

Bibliographic record

VenueClinical Journal of the American Society of Nephrology · 2025
Typereview
Languageen
FieldMedicine
TopicDiabetes Treatment and Management
Canadian institutionsMcGill UniversityMcGill University Health Centre
FundersKidney Foundation of Canada
KeywordsMedicineRenal functionKidney diseaseRandomized controlled trialHazard ratioInternal medicineMeta-analysisRelative riskConfidence intervalPlaceboHeart failureIncidence (geometry)Clinical endpointPathology

Abstract

fetched live from OpenAlex

Key Points Treatment with sodium-glucose cotransporter-2 inhibitor (SGLT-2i) provides kidney and cardiovascular protection in patients with advanced CKD. The glycosuric action of SGLT-2i is attenuated in advanced CKD resulting in no change in glycated hemoglobin and fewer volume depletion events. The use of SGLT-2i did not increase the incidence of AKI, urine infections, fractures, or treatment discontinuation due to adverse events. Background The efficacy and safety of sodium-glucose cotransporter-2 inhibitor (SGLT-2i) in patients with advanced CKD, defined as an eGFR <30 ml/min per 1.73 m 2 , has not been adequately studied. Methods We conducted a systematic review and meta-analysis of phase 3 randomized controlled trials of SGLT-2i in adults. We searched the medical literature analysis and retrieval system online and excerpta medica database databases from inception to April 2024. The primary outcomes were composite kidney (worsening kidney function, kidney failure, and kidney or cardiovascular [CV] death) and CV (CV death or hospitalization for heart failure) outcomes. Secondary outcomes included other reported CV and kidney outcomes, eGFR slopes, mechanistic, and safety outcomes. The risk ratios (RR) were estimated using a random effects model. Interaction effects were estimated for treatment effect modification by baseline eGFR (<30 and ≥30 ml/min per 1.73 m 2 ). Results A total of ten randomized controlled trials were included (total of 4800 patients with eGFR <30 ml/min per 1.73 m 2 ). Participants were randomized to receive either placebo or an SGLT-2i. The use of SGLT-2i was associated with a lower incidence of the primary composite kidney outcome in patients with eGFR <30 ml/min per 1.73 m 2 (RR, 0.79; 95% confidence interval [CI], 0.70 to 0.89) and ≥30 ml/min per 1.73 m 2 (RR, 0.71; 95% CI, 0.64 to 0.79). The incidence of the primary CV outcome was numerically lower in the SGLT-2i arm in patients with eGFR <30 ml/min per 1.73 m 2 (RR, 0.88; 95% CI, 0.71 to 1.10). In patients with eGFR ≥30 ml/min per 1.73 m 2 , SGLT-2i use was associated with a lower incidence of the composite CV outcome (RR, 0.77; 95% CI, 0.71 to 0.83). However, there was no interaction between advanced CKD status and the effect of SGLT-2i on any of the primary or secondary outcomes. The incidence of adverse events was similar in both arms. Conclusions SGLT-2i retain their kidney and CV protective effect in patients with advanced CKD, with no added safety concerns.

Fetched live from OpenAlex and de-inverted. Abstracts are not stored in this database: the inverted indexes are 8.6 GB of the frame’s 9.3 GB of text, and the host has 13 GB free.

How this classification was reachedexpand

Full frame machine prediction

Teacher imitation

Not calibrated prevalence, not ground truth. Human validation pending. The Gemma side is a direct model label for every work in the frame, read from the title-only record. The Codex side is a classifier learned from the 10,348 direct Codex labels and calibrated to design-weighted sample rates; fields without enough sample support carry no Codex call. Candidate is the union of the two sides; consensus is their intersection. These outputs are machine_predicted_unvalidated and are not human labels.

metaresearch head score (Codex)0.009
metaresearch head score (Gemma)0.023
Version: metacan-v3-hybrid-931329e0061cValidation status: machine_predicted_unvalidated
Candidate categoriesnone
Consensus categoriesnone
DomainCandidate signal: none · Consensus signal: none
Study designCandidate signal: Systematic review · Consensus signal: Systematic review
GenreCandidate signal: Review · Consensus signal: Review
Teacher disagreement score0.009
Threshold uncertainty score0.048

Distilled classifier scores by category (both heads)

CategoryCodexGemma
Metaresearch0.0090.023
Meta-epidemiology (narrow)0.0010.001
Meta-epidemiology (broad)0.0090.016
Bibliometrics0.0030.003
Science and technology studies0.0000.001
Scholarly communication0.0020.001
Open science0.0010.001
Research integrity0.0020.002
Insufficient payload (model declined to judge)0.0030.000

Machine scores (provisional)

The two teacher heads of the student model, read on this work. A score orders the frame for review; it never asserts a category, and the validation status ships verbatim with every row.

Baseline scores from an immature model (maturity gate not passed, 7 training rounds). Scores rank; they never assert a category.

Opus teacher head0.021
GPT teacher head0.345
Teacher spread0.324 · how far apart the two teachers sit on this one work
Validation statusscore_only:v0-immature-baseline · verbatim from the scoring run: score_only means the number may rank works, and no category label ships from it

Classification

machine, unvalidated

Machine predicted; a candidate call from one source (direct Gemma or distilled Codex), not a consensus.

The models applied no category: nothing in the taxonomy fit this work.
Study designSystematic review
Domainnot available
GenreReview

How this classification was reached, model by model and score by score, is at the end of the page under "How this classification was reached".

Quick stats

Citations8
Published2025
Admission routes2
Has abstractyes

Explore more

Same venueClinical Journal of the American Society of Nephrology→Same topicDiabetes Treatment and Management→French-language works237,207→